These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 2674460)

  • 1. Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens.
    Edmonson JH; McCormack GM; Wieand HS; Kugler JW; Krook JE; Stanhope CR; Everson LK; Laurie JA; Ebbert LP; Malkasian GD
    J Natl Cancer Inst; 1989 Oct; 81(19):1500-4. PubMed ID: 2674460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer.
    Anderson H; Wagstaff J; Crowther D; Swindell R; Lind MJ; McGregor J; Timms MS; Brown D; Palmer P
    Eur J Cancer Clin Oncol; 1988 Sep; 24(9):1471-9. PubMed ID: 3053207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin combined with carboplatin: a new way of intensification of platinum dose in the treatment of advanced ovarian cancer. Belgian Study Group for Ovarian Carcinoma.
    Piccart MJ; Nogaret JM; Marcelis L; Longrée H; Ries F; Kains JP; Gobert P; Domange AM; Sculier JP; Gompel C
    J Natl Cancer Inst; 1990 Apr; 82(8):703-7. PubMed ID: 2181152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot study of cyclophosphamide plus carboplatin in advanced ovarian carcinoma.
    Edmonson JH; McCormack GW; Krook JE; Long HJ; Jefferies JA; Richardson RL
    Cancer Treat Rep; 1987 Feb; 71(2):199-200. PubMed ID: 3542210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulocyte-macrophage colony-stimulating factor. Preliminary observations on the influences of dose, schedule, and route of administration in patients receiving cyclophosphamide and carboplatin.
    Edmonson JH; Hartmann LC; Long HJ; Colon-Otero G; Fitch TR; Jefferies JA; Braich TA; Maples WJ
    Cancer; 1992 Nov; 70(10):2529-39. PubMed ID: 1423182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.
    Swenerton K; Jeffrey J; Stuart G; Roy M; Krepart G; Carmichael J; Drouin P; Stanimir R; O'Connell G; MacLean G
    J Clin Oncol; 1992 May; 10(5):718-26. PubMed ID: 1569444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.
    Alberts DS; Green S; Hannigan EV; O'Toole R; Stock-Novack D; Anderson P; Surwit EA; Malvlya VK; Nahhas WA; Jolles CJ
    J Clin Oncol; 1992 May; 10(5):706-17. PubMed ID: 1569443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined carboplatin plus ifosfamide and cisplatin in patients with advanced ovarian carcinoma. A phase I-II study. GOCS (Gynecological Oncology Cooperative Study).
    Lorusso V; Leone B; Di Vagno G; Manzione L; Palmeri S; Vallejo C; Machiavelli M; Nacci G; Bilancia D; Leonardi V; Catino A; Gargano G; Loverro G; Selvaggi L; De Lena M
    Gynecol Oncol; 1998 Feb; 68(2):172-7. PubMed ID: 9514802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer.
    Hannigan EV; Green S; Alberts DS; O'Toole R; Surwit E
    Oncology; 1993 Nov; 50 Suppl 2():2-9. PubMed ID: 8233297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma.
    Evans BD; Raju KS; Calvert AH; Harland SJ; Wiltshaw E
    Cancer Treat Rep; 1983 Nov; 67(11):997-1000. PubMed ID: 6315233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose platinum chemotherapy in advanced ovarian cancer: a phase II study.
    Bertelsen K; Bastholt L
    Gynecol Oncol; 1992 Jan; 44(1):79-82. PubMed ID: 1730430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro interactions between platinum analogues in human ovarian-carcinoma cell lines.
    Perez RP; Perez KM; Handel LM; Hamilton TC
    Cancer Chemother Pharmacol; 1992; 29(6):430-4. PubMed ID: 1568285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New regimens for the treatment of gynecologic cancers].
    Sugiyama T; Ushijima K; Kamura T
    Gan To Kagaku Ryoho; 2000 Mar; 27(3):375-81. PubMed ID: 10740630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dose escalation study of carboplatin and ifosfamide in advanced ovarian cancer.
    Gallagher CJ; Wiltshaw E; Coleman RE; Harper PG
    Cancer Chemother Pharmacol; 1989; 24(1):54-7. PubMed ID: 2655961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma.
    Conte PF; Bruzzone M; Carnino F; Chiara S; Donadio M; Facchini V; Fioretti P; Foglia G; Gadducci A; Gallo L
    J Clin Oncol; 1991 Apr; 9(4):658-63. PubMed ID: 2066762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.
    Covens A; Carey M; Bryson P; Verma S; Fung Kee Fung M; Johnston M
    Gynecol Oncol; 2002 Apr; 85(1):71-80. PubMed ID: 11925123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized study comparing carboplatin/cyclophosphamide and cisplatin/cyclophosphamide as first-line treatment in patients with stage III/IV epithelial ovarian cancer and small volume disease. German Ovarian Cancer Study Group (GOCA).
    Meerpohl HG; Sauerbrei W; Kühnle H; Schumacher M; Pfleiderer A
    Gynecol Oncol; 1997 Jul; 66(1):75-84. PubMed ID: 9234925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phase I clinical study of combined cisplatin and carboplatin therapy in lung cancer].
    Hayasaka S; Yoshinaga T; Kinuwaki E; Kiyama T; Fujino N
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):2011-6. PubMed ID: 1417008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.